AstraZeneca, MSD present final results of key secondary OS endpoint from phase III PROpel trial at ASCO GU cancers symposium
By, Admin1 min read
Share
Results from the final prespecified overall survival (OS) analysis of the PROpel phase III trial in metastatic castration-resistant prostate cancer (mCRPC) showed AstraZeneca and MSD
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
